Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Development Ligand-dependent activation of the ESR1/AP-1 pathway


Log In to Post A Comment

Development Ligand-dependent activation of the ESR1/AP-1 pathway

Ligand-dependent activation of the ESR1/AP-1 pathway

Estrogen receptor 1 ( ESR1 ) is a major ligand-activated transcription factor,member of the family nuclear receptors [1]. ESR1 acts via two mainpathways: a ligand-dependent and ligand-independent [2]. Activated by aligand, ESR1 stimulates transcription directly (classical pathway), or byactivation of other transcription factors in ligand-dependent manner (non-classicalpathway ). Members of AP-1 family Jun oncogene ( c-Jun ) and v-fos FBJ murineosteosarcoma viral oncogene homolog ( c-Fos ) are a one of these transfactors[3], [4], [5].

Active ESR1 is a dimer bound to DNA at specific target sequences calledestrogen response elements [2].

17beta-estradiol is a physiological ligand of the ESR1. In the absenceof the 17beta-estradiol, ESR1 resides primarily in the nucleus, with somepresence in cytoplasm. Ligand-bound ESR1 moves to the nucleus.

In the present of 17beta-estradiol, ESR1 recruits ATP-dependentchromatin remodeling complex BAF [6], [7] toestrogen-responsive promoters. Chromatin remodeling allows recruiting co-activators suchas Nuclear receptor co-activator 1 ( NCOA1 (SRC1) ) [8] and Nuclearreceptor co-activator 2 ( NCOA2 (GRIP1/TIF2) ) [4], [5].

17beta-estradiol/ ESR1/ co-activator complex then recruits integratorproteins and histone modifying enzymes such as CREB binding protein ( CBP ) andE1A binding protein p300 ( p300 ) [3], [9], [5].

Then, ESR1 directly binds to c-Jun protein. This interaction isstabilized by the coactivator NCOA2 (GRIP1/TIF2), which interacts with bothc-Jun and ESR1 [4], [5]. In addition, NCOA1(SRC1) may participate in this process interacting with c-Jun, c-Fosand ESR1 [3].

Nuclear receptor interacting protein 1 ( RIP140 ) is a regulator in ESR1/ AP-1 pathway. RIP140 physically interacts with c-Jun and ESR1 andinhibits estradiol-induced AP-1-mediated transcription. In addition, RIP140directly binds to histone deacetylases (e.g, Histone deacetylase 4, HDAC4 ) and toco-repressor C-terminal binding protein 1 ( CtBP1 ) which itself interacts withhistone deacetylases (e.g, Histone deacetylase 1, HDAC1 ). Deacetylation ofchromatin proteins by histone deacetylases leads to inhibition of ESR1/AP-1-induced transcription [5]. In addition, CtBP1 repressesp300 -mediated transcriptional activation by direct association with itsbromodomain [10].

ESR1 may activate transcription of RIP140, thus establishing aregulatory feedback loop [11].